Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Shares of biotech company 10x Genomics (NASDAQ:TXG ... Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed ...

Get access to 10+ additional ProTips and comprehensive valuation metrics with InvestingPro's detailed research report. In other recent news, 10X Genomics announced preliminary fourth-quarter sales ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage ...

Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT ... Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium ... and the pricing challenges from the GEM-X transition are ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it ...